ONCLIVE NEWS NETWORK: ON LOCATION WILL BE LIVE AT ESMO THIS WEEK - STAY TUNED FOR MORE INFORMATION!

Dr. Yoshino Discusses the Safety Profile of TAS-102

Takayuki Yoshino, MD
Published: Monday, Jun 30, 2014

Takayuki Yoshino, MD, medical oncologist, National Cancer Center Hospital East, Chiba, Japan, discusses the safety profile of TAS-102 as seen in a phase III study of the agent versus placebo with best supportive care in patients with metastatic colorectal cancer (mCRC) refractory to standard therapies.

Yoshino says that TAS-102 is well tolerated overall with very mild toxicity. The most common adverse events observed in the TAS-102 arm were hematologic, including anemia (16.5%) and neutropenia (34.9%).

There were also some incidences of diarrhea, pyrexia and vomiting, Yoshino says, but these were generally manageable. Based on this, Yoshino says he believes that TAS-102 is very well tolerated in almost all patients.

<<< View more from the 2014 World GI Congress

Takayuki Yoshino, MD, medical oncologist, National Cancer Center Hospital East, Chiba, Japan, discusses the safety profile of TAS-102 as seen in a phase III study of the agent versus placebo with best supportive care in patients with metastatic colorectal cancer (mCRC) refractory to standard therapies.

Yoshino says that TAS-102 is well tolerated overall with very mild toxicity. The most common adverse events observed in the TAS-102 arm were hematologic, including anemia (16.5%) and neutropenia (34.9%).

There were also some incidences of diarrhea, pyrexia and vomiting, Yoshino says, but these were generally manageable. Based on this, Yoshino says he believes that TAS-102 is very well tolerated in almost all patients.

<<< View more from the 2014 World GI Congress


View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: 18th Annual International Lung Cancer Congress®Oct 31, 20181.5
Provider and Caregiver Connection™: Addressing Patient Concerns While Managing Chemotherapy Induced Nausea and VomitingOct 31, 20182.0
Publication Bottom Border
Border Publication
x